Gilead Sciences
The global landscape of HIV prevention and treatment has reached a historic turning point following the clinical triumph and subsequent commercial launch of Gilead Sciences’ (Nasdaq: GILD) lenacapavir, now marketed as Yeztugo. As of February 25, 2026, the biopharmaceutical giant has successfully transitioned from a provider of daily oral regimens
Gilead Sciences
As of February 13, 2026, the financial markets are witnessing a historic "Great Rotation," where institutional capital is flowing out of overextended technology valuations and into the defensive, high-yield corridors of the healthcare sector. At the center of this movement is Gilead Sciences (Nasdaq: GILD), which has defied
Earnings Season
The second quarter 2025 earnings season has largely concluded, delivering a powerful shot of optimism to the financial markets. Against a backdrop of persistent economic uncertainties and geopolitical tensions, a surprising number of U.S. corporations have not only met but significantly exceeded analyst expectations for both earnings and revenue.
Earnings Season
The second quarter of 2025 has largely concluded as a period of unexpected strength for U.S. corporations, with a significant number of companies not only meeting but exceeding analyst expectations. This positive trend has injected a renewed sense of optimism into the financial markets, showcasing the resilience of various